The/DT
use/NN
of/IN
glucocorticoids/NNS
in/IN
acute/JJ
lymphoblastic/JJ
leukemia/NN
of/IN
childhood/NN
./.
=====
Molecular/JJ
,/,
cellular/JJ
,/,
and/CC
clinical/JJ
considerations/NNS
./.

Glucocorticoids/NNS
have/VBP
been/VBN
included/VBN
in/IN
almost/RB
all/DT
treatment/NN
regimens/NNS
for/IN
childhood/NN
acute/JJ
lymphoblastic/JJ
leukemia/NN
for/IN
decades/NNS
./.
=====
However/RB
,/,
optimal/JJ
agents/NNS
,/,
doses/NNS
,/,
and/or/CC
schedules/NNS
have/VBP
yet/RB
to/TO
be/VB
defined/VBN
despite/IN
extensive/JJ
clinical/JJ
application/NN
./.
=====
New/JJ
data/NNS
on/IN
the/DT
pharmacokinetics/NNS
,/,
pharmacodynamics/NNS
,/,
and/CC
molecular/JJ
mechanisms/NNS
of/IN
action/NN
of/IN
glucocorticoids/NNS
have/VBP
suggested/VBN
alternative/JJ
approaches/NNS
in/IN
ALL/NN
./.
=====
These/DT
suggest/VBP
that/IN
prolonged/JJ
,/,
i.e./FW
28/CD
day/NN
,/,
glucocorticoid/NN
therapy/NN
may/MD
be/VB
unnecessary/JJ
as/IN
exposure/NN
to/TO
glucocorticoid/NN
induces/VBZ
down-regulation/NN
of/IN
glucocorticoid/NN
receptors/NNS
./.
=====
Dexamethasone/NN
may/MD
be/VB
superior/JJ
to/TO
prednisone/NN
in/IN
conventional/JJ
equi-effective/JJ
doses/NNS
./.
=====
Blast/NN
sensitivity/NN
to/TO
glucocorticoids/NNS
correlates/VBZ
closely/RB
with/IN
sensitivity/NN
to/TO
other/JJ
,/,
putatively/RB
non-cross-resisting/JJ
agents/NNS
and/CC
with/IN
outcome/NN
after/IN
multi-agent/JJ
therapy/NN
,/,
suggesting/VBG
overlapping/JJ
mechanisms/NNS
of/IN
action/NN
,/,
and/CC
focusing/VBG
attention/NN
on/IN
the/DT
determinants/NNS
of/IN
the/DT
threshold/NN
for/IN
apoptosis/NN
./.
=====
Increasing/VBG
success/NN
in/IN
the/DT
treatment/NN
of/IN
childhood/NN
acute/JJ
lymphoblastic/JJ
leukemia/NN
has/VBZ
led/VBN
to/TO
increasing/VBG
awareness/NN
of/IN
avascular/JJ
necrosis/NN
of/IN
bone/NN
as/IN
a/DT
potentially/RB
disabling/JJ
sequela/NN
of/IN
glucocorticoid/NN
therapy/NN
,/,
especially/RB
in/IN
adolescent/JJ
and/CC
young/JJ
adult/JJ
patients/NNS
./.